Statines in treatment of patients with diabetes mellitus: niche of atorvastatine
https://doi.org/10.21518/2079-701X-2018-4-54-59
Abstract
The review is devoted to the features of statin therapy in patients with type 2 diabetes to prevent serious cardiovascular complications.
About the Author
S. A. Urazgildeeva
St. Petersburg State University;
Clinical Hospital No. 122;
Chernaya Rechka Center for Cardiac Medicine
Russian Federation
Russian Federation
MD
Cardiology Research Clinical and Educational Center of the Medical Faculty of St. Petersburg State University;
Sokolov Center for Atherosclerosis and Lipid Disorders in Clinical Hospital No. 122;
Center for Clinical Lipidology of Chernaya Rechka Center for Cardiac Medicine
St. Petersburg
References
1. IDF Diabetes Atlas, 7th Edition, 2015. http://www.diabetesatlas.org/resources/2015-atlas.html.
2. Standards of specialized medical care in diabetes mellitus, 8th edition, 2017. Edited by Dedova II, Shestakova MV. Sakharniy Diabet, 2017, 20 (1S): 1-112.
3. Yusuf S, Hawken S, Ounpuu S et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 coutries (the INTERHEART Study): case-control study. Lancet, 2004, 364(9438): 937-952.
4. ESC/EAS Guidelenes for the Management of Dyslipidemias: The Task Force for the Management of Dyslipidemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Atherosclerosis, 2016, 253: 281-344.
5. Diagnosis and correction of lipid metabolism disorders for the prevention and management of atherosclerosis. Russian guidelines VI revision. Ateroskleroz i Dislipidemii, 2017, 3: 2-22.
6. Glinkina IV. Treatment of lipid metabolism disorders in type 2 diabetes mellitus. Lechashchiy Vrach, 2002, 6: 6-8
7. Sniderman AD, Lamarche B, Tilley J et al. Hypertriglyceridemic hyperapo B in type 2 diabetes. Diabetes Care, 2002, 25(3): 579-582.
8. Features of dyslipidemia management in patients with type 2 diabetes mellitus. Meditsinskiy Sovet, 2016, 3: 48-53.
9. Alekseeva IA, Sergienko IV. The role of atorvastatin in the secondary prevention of cardiovascular diseases in the light of contemporary guidelines. Ateroskleroz i Dislipidemii, 2017, 3: 23-32
10. Kwiterovich PO. Dyslipidemia in Special Groups. Dyslipidemia, 2010: 124.
11. Colhoun HM, Betteridge D.J., Durrington P.N. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 369: 685-696.
12. Sever PS, Dahlöf B, Poulter NL et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet, 2003, 361: 1149-1158.
13. Poulter NL, Sever PS, Dahlöf B et al. Role of blood pressure and other variables in the differential cardiovascular event noted in the -Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 2005, 366: 907-913.
14. Shepherd J, Barter P, Carmena R et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care, 2006, 29: 1220-1226.
15. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2014, 129, 25(Suppl. 2): 1-45.
16. Newman C, Tsai J, Szarek M et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Amer. J. Cardiol., 2006, 97(1): 61-67.
17. De Zeeuw D., Anzalone DA, Cain VA et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol, 2015, 3: 181-190.
18. Gurevich VS, Urazgildeeva SA, Shatilina LV. Changes in the levels of antibodies to oxidized lipoproteins in the treatment of atorvastatin in women with coronary heart disease in postmenopausal women. Cardiologiya, 2004, 44 (4): 76-77.
Review
For citations:
Urazgildeeva SA. Statines in treatment of patients with diabetes mellitus: niche of atorvastatine. Meditsinskiy sovet = Medical Council. 2018;(4):54-59. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-54-59
Views:
673
Email this article 